Predilife SA

Predilife operates with a negative equity position of EUR -4.27 million and a debt-to-equity ratio of -1.16, indicating a capital structure dominated by liabilities. The company’s liquidity position is constrained, with cash and equivalents of EUR 350,500 and a current ratio of 1.37, suggesting limited capacity to meet short-term obligations. Free cash flow is negative at EUR -4.24 million, reflecting ongoing operational cash outflows. Profitability metrics are weak, with a net loss of EUR -4.26 million and an operating loss of EUR -4.50 million. Return on equity is 0.9992, while return on assets is -1.7452, both significantly below industry benchmarks for biotechnology firms. Gross profit of EUR 479,380 is insufficient to offset operating expenses, highlighting inefficiencies in cost management. Predilife’s revenue is concentrated in a single product, MammoRisk, with no disclosed geographic diversification. The company’s EUR 493,200 in revenue is entirely attributed to its breast cancer predictive testing segment, exposing it to market-specific risks. Analysts project a modest revenue increase to EUR 690,000, but this remains speculative given the company’s current financial position. Outlook for the current fiscal year is negative, with analysts forecasting a EUR -1.20 EPS and EUR -4.43 million EBIT. The company’s free cash flow is expected to remain negative, with no indication of near-term improvement in operating cash flow. Capital expenditures are minimal at EUR -5,400, suggesting limited investment in growth. Risk factors include high leverage, with long-term debt of EUR 4.94 million and a negative equity position. The company’s liquidity risk is rated as medium, with cash reserves insufficient to cover debt obligations. Dilution risk is low, as shares outstanding remain unchanged between basic and diluted measures. Recent filings indicate ongoing losses and a reliance on external financing. The company’s 10-K Risk Factors section highlights exposure to regulatory changes in medical diagnostics and competition from established players. Analyst transcripts suggest limited visibility on long-term revenue drivers, with MammoRisk’s adoption rate being the primary growth lever.